Latest News
Latest News
When digestive symptoms signal Parkinson’s disease
It therefore remains to be determined whether vagal nerve damage alone can explain gastrointestinal disorders or whether dysfunction of enteric...
Conference Coverage
Playing board games may slow cognitive decline, improve QoL
Playing a board game involves concentration, strategy, and intermittent rewards – all of which are good for the brain and may involve the...
Conference Coverage
NMO: Study says double diagnoses with MS are common
Nearly half of patients with coding for NMO were also listed as having MS – a very similar condition.
Conference Coverage
EBV and MS: Just how deep is the link?
Two MS researchers disagree over how tightly they’re connected, and one says “second hit” may be factor.
Latest News
Prior authorization software: Saves time but hurdles remain
The automation works, but the software can be costly and may not work for all practices.
Conference Coverage
Stem cell transplants in early MS: Who benefits most?
Neurologists outline findings as the MS field works toward consensus on HSCT as rescue therapy.
Conference Coverage
MS-tailored weight loss program achieves meaningful results
Weight loss “was associated with improved mobility, reduced fatigability, and improved physical quality of life.”
From the Journals
Are migraine preventives underused in young adults?
While researchers suggest their findings could show underuse of preventive migraine medications in young adults, an expert notes the reality is...
30th Anniversary
From failure to hope: Tracking the changing landscape of Alzheimer’s therapies
The Alzheimer's Drug Development Pipeline report, updated annually since 2016, classifies Alzheimer's therapies by their targets, their mechanisms...
Conference Coverage
‘We’re halfway home’: UCSF’s Dr. Stephen Hauser sketches MS future
Identification of a reliable MS biomarker as well as early detection and intervention will be key going forward.
Conference Coverage
Next up in MS trials: More insight into progressive disease
Results from several treatment trials in progressive MS are expected over the next 2 years.